Show simple item record

dc.contributor.authorBrekke, Kurt R.
dc.contributor.authorDalen, Dag Morten
dc.contributor.authorStraume, Odd Rune
dc.date.accessioned2023-11-22T08:35:25Z
dc.date.available2023-11-22T08:35:25Z
dc.date.issued2023-11-22
dc.identifier.issn0804-6824
dc.identifier.urihttps://hdl.handle.net/11250/3104002
dc.description.abstractWe study the competitive effects of combination therapies in pharmaceutical markets, which crucially hinge on the additional therapeutic value of combinatory use of drugs and the therapeutic substitutability with the most relevant monotherapy. With large additional therapeutic value, the introduction of combination therapies leads to higher prices and, somewhat paradoxically, may reduce the health plan's surplus. Although combination therapies imply that drugs become both substitutes and complements, we show that drug prices increase if the firms are allowed to coordinate their prices. Allowing for price discrimination might increase allocational efficiency, but only at the expense of higher purchasing costs.en_US
dc.language.isoengen_US
dc.publisherInstitutt for samfunnsøkonomien_US
dc.relation.ispartofseriesDP SAM;19/2023
dc.subjectPharmaceutical marketsen_US
dc.subjectCombination therapiesen_US
dc.subjectTherapeutic competitionen_US
dc.titleTaking the competitor’s pill: when combination therapies enter pharmaceutical marketsen_US
dc.typeWorking paperen_US
dc.subject.nsiVDP::Samfunnsvitenskap: 200en_US
dc.source.pagenumber38en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record